Showing 1 - 8 results of 8 for search 'Dafna D Gladman', query time: 0.03s Refine Results
  1. 1
    Identification of miR‐190a‐5p and miR‐26b‐5p as Potential microRNA Biomarkers for Psoriatic Arthritis

    Identification of miR‐190a‐5p and miR‐26b‐5p as Potential microRNA Biomarkers for Psoriatic Arthritis by Omar F. Cruz‐Correa, Darshini Ganatra, Ameth N. Garrido, Rohan Machhar, Starlee Lively, Mohit Kapoor, Dafna D. Gladman

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis

    Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized c... by Dafna D. Gladman, Peter Nash, Philip J. Mease, Oliver FitzGerald, Stephanie Duench, Mary Jane Cadatal, Karim R. Masri

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus

    Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus by Murray B Urowitz, Dafna D Gladman, Jiandong Su, Zahi Touma, Paula Harvey, Jagan Sivakumaran, Ahmed Omar, Oshrat Tayer-Shifman, Nicole Anderson

    Published 2021-04-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

    Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to con... by Philip J Mease, Dafna D Gladman, Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, Daniela Graham, Cunshan Wang, Joseph C Cappelleri, Thijs Hendrikx, Ming-Ann Hsu

    Published 2019-05-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis

    Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic... by Laure Gossec, Ana-Maria Orbai, Maarten de Wit, Dafna D Gladman, Laura C Coates, Alexis Ogdie, Vanessa Taieb, Jeremy Lambert, Barbara Ink, Christopher G Pelligra, Valérie Ciaravino

    Published 2024-02-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond

    Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, ran... by Philip J Mease, Dafna D Gladman, Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, Joseph C Cappelleri, Thijs Hendrikx, Ming-Ann Hsu, Linda Chen, Elizabeth Kudlacz, Joseph Wu

    Published 2019-06-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

    Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III... by Robert Landewé, Joseph F Merola, Laure Gossec, Frank Behrens, Ana-Maria Orbai, Philip J Mease, Iain B McInnes, Yoshiya Tanaka, Dafna D Gladman, Laura C Coates, Alice B Gottlieb, Vishvesh Shende, Jason Coarse, Christopher T Ritchlin, Richard B Warren, Akihiko Asahina, Barbara Ink, Rajan Bajracharya

    Published 2024-02-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Functional work disability from the perspectives of persons with systemic lupus erythematosus: a qualitative thematic analysis

    Functional work disability from the perspectives of persons with systemic lupus erythematosus: a qualitative thematic analysis by Behdin Nowrouzi-Kia, Aaron S. Howe, Anson Li, Jeremy Tan, Natalia Saade-Cleves, Kevon Jules, Malak Sadek, Ali Bani-Fatemi, Antonio Avina-Zubieta, Mary T. Fox, William Shaw, Derek Haaland, Janet Pope, Paul R. Fortin, Kathleen S. Bingham, Christine Peschken, Jennifer Reynolds, Catherine Ivory, Dafna D. Gladman, Murray B. Urowitz, Jorge Sanchez-Guerrero, Lily S. H. Lim, Stephanie Keeling, Patti Katz, Mahta Kavkan, Dennisse Bonilla, Wils Nielsen, Zahi Touma

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: